Scilex Holding Company (SCLXW)Palo Alto, United States | NasdaqCM
0.16 USD
0.00
(-1.251%) ⇩
(Aug. 28, 2026, 10:03 a.m.
EDT)
|
Hot Take ↕ | Aug. 22, 2026, 3:33 a.m. EDT
The security is trading at its 52-week low of $0.1051, indicating severe near-term weakness as it tests critical support levels amid thin volume. The technical picture is dire, with the stock sliding nearly 10% recently and showing no signs of a recovery, warranting a strong sell signal for the immediate future. From a long-term perspective, the business fundamentals are catastrophically broken: the company carries massive debt ($106M) against negligible cash ($3.4M), resulting in a negative book value of -$29.54 and a current ratio of just 0.084, signaling imminent liquidity distress. Despite a reported 72% revenue growth, the operating margins are -373%, and the return on assets is -92%, proving that top-line expansion is failing to generate any economic value. The recent news confirms a worsening situation, with the bankruptcy court extending a lockup period on shares until April 2025, further entrenching uncertainty. There is no dividend to speak of, and the combination of insolvency risks and operational losses makes this a clear avoid. |
| Attribute | Value |
|---|---|
| Revenue per Share | 3.637 |
| Beta | 1.74 |
| Website | https://www.scilexholding.com |
| Attribute | Value |
|---|---|
| Address1 | 960 San Antonio Road |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 1.742 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -29.544 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.1579 |
| Current Ratio | 0.071 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.1599 |
| Day Low | 0.1579 |
| Display Name | Scilex Holding |
| Ebitda | -277,268,000 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.1599 |
| Fifty Two Week High Change | -0.0019999892 |
| Fifty Two Week High Change Percent | -0.01250775 |
| Fifty Two Week Low | 0.1579 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.1579 - 0.1599 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 5,690,047 |
| Free Cashflow | -8,842,550 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 34 |
| Fullday Change | -0.0019999892 |
| Fullday Change Percent | -1.250775 |
| Fullday Price | 0.1579 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.55495 |
| Gross Profits | 17,541,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California. |
| Long Name | Scilex Holding Company |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_607715156 |
| Net Income To Common | -448,344,992 |
| Open | 0.17 |
| Operating Cashflow | -17,085,000 |
| Operating Margins | -3.85017 |
| Phone | 650 516 4310 |
| Previous Close | 0.1599 |
| Price Hint | 4 |
| Price To Book | -0.005344571 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.051 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0019999892 |
| Regular Market Change Percent | -1.250775 |
| Regular Market Day High | 0.1599 |
| Regular Market Day Low | 0.1579 |
| Regular Market Day Range | 0.1579 - 0.1599 |
| Regular Market Open | 0.17 |
| Regular Market Previous Close | 0.1599 |
| Regular Market Price | 0.1579 |
| Regular Market Time | 1,787,925,780 |
| Regular Market Volume | 1,814 |
| Return On Assets | -1.0583 |
| Revenue Growth | -0.228 |
| Revenue Per Share | 3.637 |
| Sand P52 Week Change | 0.1966995 |
| Sector | |
| Sector Key | |
| Source Interval | 15 |
| State | CA |
| Symbol | SCLXW |
| Total Cash | 581,000 |
| Total Cash Per Share | 0.083 |
| Total Debt | 105,985,000 |
| Total Revenue | 31,608,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 1,814 |
| Website | https://www.scilexholding.com |
| Zip | 94,303 |